Having reached a benchmark in trials for a new cardiovascular drug, Corautus Genetics has closed on an additional $7.2 million in financing.

Its Genasis (Genetic Angiogenic Stimulation Investigational Study) drug recently entered Phase Iib trial.

The milestone enabled Corautus to close on $4.7 million in a private placement of stocks and warrants. Coarautus also received $2.5 million in debt financing from Boston Scientific as part of a $25 million commitment. Coarautus has drawn $20 million from that agreement.

Corautus: www.corautus.com